Operational cash flow remains consistently negative, highlighted by a $831.1K free cash flow outflow in 2025Q2 and an OCF/NI ratio that reached an extreme 29.99 in the same period.
| Cash from Operations | -101.74K | -181.46K | -2.13M | -2.96M | -741.45K | -473.98K |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | 316.89% | 91.47% | 28.25% | -299.71% | -56.43% | - |
| Net Income | -204.12K | -101.52K | -2.78M | -3.73M | -4.03M | -1.84M |
| Depreciation & Amortization | 50.84K | 10.71K | 399.6K | 365.23K | 126.63K | 57.85K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 62.77K | 0 | 0 | 150.21K | 1.66M | 0 |
| Working Capital Changes | -15.85K | -90.65K | 256.34K | 253.71K | 1.5M | 1.31M |
| Change in Receivables | 0 | 0 | 53.49K | 21.4K | 243 | 28 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -16.03K | -3.67K | 479.63K | 381.25K | 912.42K | 17.24K |
| Cash from Investing | -1.18K | -985 | -74.11K | -263.01K | -1.08M | -25.44K |
| Capital Expenditures | -1.18K | -985 | -74.11K | -210.88K | -889.59K | -25.44K |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | -50.49K | 199.53K | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -1.64K | -393.62K | 0 |
| Cash from Financing | 21.24K | 184.87K | 1.87M | 458.14K | 6.1M | 697.16K |
| Debt Issued (Net) | 18.75K | 13.72K | 1.66M | 0 | 0 | 0 |
| Equity Issued (Net) | 15.58K | 171.14K | -2.68K | 1.01M | 6.1M | 697.16K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -13.08K | 0 | 212.18K | -553.47K | 0 | 0 |
| Net Change in Cash | -74.72K | 19.02K | -14.31K | -2.16M | 4.72M | 217 |
| Free Cash Flow | -102.93K | -182.45K | -2.2M | -3.18M | -2.05M | -499.42K |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | 97.87% | 91.71% | 30.72% | -54.66% | -311.2% | - |
| FCF per Share | -0.08 | -0.01 | -0.10 | -0.03 | -0.02 | -0.02 |
| FCF Conversion (FCF/Net Income) | 0.50x | 1.79x | 0.76x | 0.79x | 0.18x | 0.26x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Pre-revenue clinical execution risk
According to the provided financial data, the OCF/NI ratio has exhibited extreme volatility, reaching a peak of 29.99 in 2025Q2, which suggests that reported net income figures are currently decoupled from the underlying cash reality of the company's pre-commercial diagnostic operations and clinical trial expenditures.
The wide variance between net income and operating cash flow indicates that non-cash items or accounting adjustments are significantly distorting the bottom line. Investors should interpret these figures with caution, as the lack of a consistent relationship between earnings and cash flow makes it difficult to assess the true operational efficiency of the business.
As reported in financial statements, ADVB has consistently generated negative free cash flow over the last ten quarters, with a notable cash outflow of $831.1K in 2025Q2, highlighting the company's ongoing reliance on its substantial cash reserves to fund its R&D and clinical expansion.
The persistent negative trajectory of free cash flow is typical for a pre-revenue entity, yet the scale of these outflows relative to the company's operational stage warrants close monitoring. The absence of a clear path to positive cash flow suggests that the company remains in a high-risk phase of capital consumption.
Based on the reported figures, working capital changes have fluctuated wildly, ranging from a $179.6K inflow in 2024Q4 to a $64.0K outflow in 2025Q3, which may indicate significant instability in the company's management of payables and receivables as it scales its clinic operations.
Such volatility in working capital often points to challenges in coordinating cash flows across international borders, particularly given the company's clinic footprint in China. This inconsistency may imply that the company is struggling to establish a predictable cash conversion cycle, which is essential for long-term operational sustainability.
Financial statements reveal that depreciation and amortization expenses, such as the $153.9K recorded in 2024Q4, are significant relative to cash flow, suggesting that the company is heavily investing in tangible assets despite its pre-revenue status and the inherent risks of its diagnostic hardware model.
The reliance on D&A to bridge the gap between net income and cash flow suggests that the company is capitalizing costs that might otherwise be expensed. Analysts should investigate whether these capitalized costs are truly reflective of long-term asset value or if they represent an attempt to smooth the appearance of operational losses.
Quick answers to the most common questions about buying ADVB stock.
Advanced Biomed Inc. Common Stock (ADVB) generated $-0.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Advanced Biomed Inc. Common Stock (ADVB) reported negative free cash flow of $0.2M in 2025, indicating capital requirements exceeded cash from operations.
Advanced Biomed Inc. Common Stock (ADVB) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.